Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery

CRISPR/Cas9 technology has revolutionised the ability of scientists to make genetically modified cells and animal models. Here, the authors make a Tet-On genetically modified mouse using the Streptococcus pyogenes Cas9 and demonstrate that it can be used for generation of mice with lung cancer.

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Anders Lundin, Michelle J. Porritt, Himjyot Jaiswal, Frank Seeliger, Camilla Johansson, Abdel Wahad Bidar, Lukas Badertscher, Sandra Wimberger, Emma J. Davies, Elizabeth Hardaker, Carla P. Martins, Emily James, Therese Admyre, Amir Taheri-Ghahfarokhi, Jenna Bradley, Anna Schantz, Babak Alaeimahabadi, Maryam Clausen, Xiufeng Xu, Lorenz M. Mayr, Roberto Nitsch, Mohammad Bohlooly-Y, Simon T. Barry, Marcello Maresca
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2020
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/8d05a4aa843b419591409ca746b331db
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery

Documents similaires